Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2014


Biosimilars and Biobetters

29 Sep 2014 - 30 Sep 2014 - London, UK



Bookmark and Share


The industry leading Biosimilars & Biobetters Conference for combining new biosimilars and biobetter developments with essential networking opportunities, will be taking place in London, on the 29th-30th of September 2014. 

With an in-depth focus on the current and future landscape of the biosimilars market, this year's conference will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join this event and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

KEY TOPICS INCLUDE:

  • Optimizing the commercial potential of biosimilars in Europe 
  • The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry 
  • What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry 
  • Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars... and much more!

KEY SPEAKERS INCLUDE:

  • Alan Sheppard, Global Head Generics, Thought Leadership, IMS Health 
  • Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals 
  • Uwe Gudat, Head of Safety Biosimilars, Merck Switzerland Limited 
  • Catherine Akers, Regulatory Affairs Manager, Amgen Inc  
  • Carsten Brockmeyer, Founder, Formycon AG 
  • Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, Medimmune (AstraZeneca Biologics) 
  • Ineke Braat, CEO, Pan-Generika 
  • Sharma Alok, Principal Scientist & Head Analytical Development, Lupin Laboratories Ltd 
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency 
  • Peter Wittner, Senior Consultant, Interpharm Consultancy 
  • Sarah Faircliffe, Legal Director, Bird & Bird...

Plus, many more at this year's event.

For more information, contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk

For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk

Event website: www.smi-online.co.uk/2014biosimilars65.asp



Further information
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!